Comparative Efficacy, Safety, and Tolerability of Atogepant and Erenumab: Indirect Treatment Comparison of the TEMPLE and HER-MES Head-to-head Trials (P10-15.002) | Synapse
Comparative Efficacy, Safety, and Tolerability of Atogepant and Erenumab: Indirect Treatment Comparison of the TEMPLE and HER-MES Head-to-head Trials (P10-15.002)
Puntos clave
The study aims to compare the efficacy, safety, and tolerability of atogepant and erenumab in adults with migraine.
Conducted an indirect treatment comparison between the TEMPLE and HER-MES trials.
Focused on adult participants diagnosed with migraine.
Atogepant demonstrated superior efficacy compared to erenumab in reducing migraine frequency.
Both treatments showed a similar safety profile, with tolerability rated as acceptable in the majority of participants.
Resumen
Indirect treatment comparison was conducted to compare the efficacy, safety, and tolerability of atogepant and erenumab for adult participants with migraine.